Compare Amgen, Inc. (AMGN) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Liberty Global Ltd Class C — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Liberty Global Ltd Class C trades at $10.27 (market cap $3.55B). The key difference: Amgen, Inc. is far larger — about 55.2× Liberty Global Ltd Class C's market cap, and Amgen, Inc. pays a 2.77% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| AMGN | LBTYK | |
|---|---|---|
Market Cap | $196.12B | $3.55B |
Sector | Health | Technology |
52-Week High | $388.16 | $12.67 |
52-Week Low | $271.18 | $10.07 |
Enterprise Value | $241.41B | $10.83B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LBTYK trades at $10.27, down 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights the planned 2027 Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly bullish with 69% buy ratings, viewing the stock as a sum-of-the-parts opportunity trading below intrinsic value.
The investment case hinges on the Ziggo Group spin-off unlocking value, with potential upside to $27 per share according to bullish analysts. However, persistent net losses, high debt, and execution risks around the listing pose significant threats. The stock offers high risk-reward for investors betting on successful corporate restructuring and operational turnaround by 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
